Regulatory Approval

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

ITM’s promising cancer drug ITM-11 hits a delay, not for its science, but for manufacturing. A classic 'prototype to profit' hurdle with big implications.

As the ashwagandha market booms, quality concerns rise. OmniActive's Zenroot secures USP verification, offering a trusted, low-dose solution for brands.

Health Canada's approval of Fasenra for HES marks a new era for patients. This is the story of how one drug intersects with patient hope and national policy.

With SEC approval, Auddia's transformative merger into AI holding company McCarthy Finney enters its final phase, setting the stage for a shareholder vote.

Partner Ocumension submits NCX 470 for approval, a move poised to tap into a massive patient market and validate Nicox's global commercialization strategy.

How an actuarial firm’s new certification to use sensitive pseudonymized data positions it at the center of Japan’s ambitious healthcare transformation.

A key partner's FDA stumble could have derailed a vital new SMA drug. Instead, Scholar Rock's foresight kept the approval on track, showing why it pays to plan for the worst.

A massive earnings jump masks underlying operational costs. HEI leverages its wildfire settlement clarity to launch a huge renewable energy and grid hardening plan.

NRx Pharmaceuticals announces a key FDA milestone for its ketamine therapy. This is a critical step, but the path to patient access is complex.

European approval for Bavarian Nordic's pediatric mpox vaccine is a critical health breakthrough and a masterclass in strategic market positioning.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

With its Duchenne therapy nearing a pivotal FDA meeting, Solid Biosciences isn't just developing a drug; it's building a network for genetic repair.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

Zentalis Pharmaceuticals is pursuing a dual strategy for its ovarian cancer drug, azenosertib, aiming for fast market entry while securing long-term validation.

Apyx Medical's Q2 results show a 28% surge in its aesthetics unit, driven by the new AYON system. Is this strategic pivot away from OEM the key to its future?

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

Crypto trading powerhouse Wintermute has gained SEC and FINRA approval, positioning it to compete with Wall Street giants and reshape institutional access to digital assets.

Cryoport hits a key profitability milestone, but the real story is its tightening grip on the booming gene therapy market. Is this a true turning point?